|
KR102508166B1
(ko)
|
2014-04-10 |
2023-03-13 |
시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 |
세포 면역요법을 위한 방법 및 조성물
|
|
ES2836743T3
(es)
*
|
2014-06-02 |
2021-06-28 |
Us Health |
Receptores de antígeno quiméricos que seleccionan como diana CD-19
|
|
US10738116B2
(en)
|
2015-03-19 |
2020-08-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Dual specific anti-CD22-anti-CD19 chimeric antigen receptors
|
|
MX2018001568A
(es)
|
2015-08-07 |
2019-04-25 |
Seattle Children´S Hospital Dba Seattle Children´S Res Institute |
Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
|
|
WO2017070042A1
(en)
|
2015-10-20 |
2017-04-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing t cell populations using akt inhibitors
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
CN105906720A
(zh)
*
|
2016-05-16 |
2016-08-31 |
武汉汉密顿生物科技股份有限公司 |
靶向性嵌合抗原受体修饰的免疫细胞及其制备方法和应用
|
|
CN105949324B
(zh)
*
|
2016-06-30 |
2019-08-27 |
上海恒润达生生物科技有限公司 |
靶向gpc3的嵌合抗原受体及其用途
|
|
CN105949325B
(zh)
*
|
2016-07-08 |
2019-07-16 |
重庆精准生物技术有限公司 |
包含cd27胞内结构域的嵌合抗原受体、慢病毒载体及其应用
|
|
WO2018045325A1
(en)
|
2016-09-02 |
2018-03-08 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with duocars
|
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
CN107936120B
(zh)
*
|
2016-10-13 |
2021-03-09 |
上海赛比曼生物科技有限公司 |
Cd19靶向性的嵌合抗原受体及其制法和应用
|
|
WO2018132494A1
(en)
*
|
2017-01-10 |
2018-07-19 |
Intrexon Corporation |
Modulating expression of polypeptides via new gene switch expression systems
|
|
US11963966B2
(en)
|
2017-03-31 |
2024-04-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
US20200071773A1
(en)
|
2017-04-12 |
2020-03-05 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
|
EP3622092A4
(en)
|
2017-05-11 |
2021-06-23 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
|
|
CN110914289B
(zh)
*
|
2017-05-12 |
2024-05-14 |
克里斯珀医疗股份公司 |
用于工程化细胞的材料和方法及其在免疫肿瘤学中的用途
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
CA3062433A1
(en)
|
2017-05-15 |
2018-11-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bicistronic chimeric antigen receptors and their uses
|
|
IL270990B2
(en)
|
2017-06-07 |
2024-02-01 |
Precigen Inc |
Expression of new cell markers
|
|
US11897953B2
(en)
|
2017-06-14 |
2024-02-13 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
WO2019014581A1
(en)
|
2017-07-14 |
2019-01-17 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
|
|
WO2019030757A1
(en)
*
|
2017-08-09 |
2019-02-14 |
Ctg Pharma Ltd. |
CHIMERIC ANTIGEN RECEPTOR FOR HER2 / NEU AND LYMPHOCYTES T THE EXPRESSANT
|
|
WO2019070755A1
(en)
|
2017-10-02 |
2019-04-11 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
|
|
WO2019075055A1
(en)
|
2017-10-11 |
2019-04-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
METHODS FOR PRODUCING T-CELL POPULATIONS USING P38 MAPK INHIBITORS
|
|
WO2019084055A1
(en)
|
2017-10-23 |
2019-05-02 |
Massachusetts Institute Of Technology |
CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
|
|
WO2019094955A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
|
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
|
US11708409B2
(en)
|
2017-12-22 |
2023-07-25 |
Abclon Inc. |
Antibody or antigen-binding fragment thereof that specifically recognizes B cell malignancies, chimeric antigen receptor comprising same, and uses thereof
|
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
|
US20210052647A1
(en)
|
2018-02-09 |
2021-02-25 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Tethered interleukin-15 and interleukin-21
|
|
EP3757133A4
(en)
|
2018-02-11 |
2021-12-01 |
Jiangsu Hengrui Medicine Co., Ltd. |
ISOLATED ANTIGENIC CHEMICAL RECEPTOR, MODIFIED T LYMPHOCYTE INCLUDING IT AND ASSOCIATED USE
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
IL278348B2
(en)
|
2018-05-11 |
2025-03-01 |
Crispr Therapeutics Ag |
Methods and preparations for treating cancer
|
|
IL321548A
(en)
|
2018-05-22 |
2025-08-01 |
Immunitybio Inc |
Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
|
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
CN108841792A
(zh)
*
|
2018-06-14 |
2018-11-20 |
浙江大学 |
靶向cd19和ebna1基因修饰的t细胞及其制备方法与应用
|
|
CN108864307A
(zh)
*
|
2018-07-23 |
2018-11-23 |
北京多赢时代科技有限公司 |
信号肽优化靶向cd19的嵌合抗原受体、表达该嵌合抗原受体的t细胞及制备方法和应用
|
|
CN110819678A
(zh)
*
|
2018-08-07 |
2020-02-21 |
上海恒润达生生物科技有限公司 |
一种评估cart细胞有效性的方法
|
|
EP3852788A1
(en)
*
|
2018-09-17 |
2021-07-28 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses
|
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
|
WO2020092455A2
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
|
AU2019372673A1
(en)
|
2018-11-01 |
2021-05-27 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Compositions and methods for T cell engineering
|
|
WO2020114358A1
(zh)
*
|
2018-12-03 |
2020-06-11 |
广东东阳光药业有限公司 |
Cd19抗体及其应用
|
|
MX2021006968A
(es)
|
2018-12-12 |
2021-10-13 |
Kite Pharma Inc |
Antígeno quimérico y receptores de las células t, y métodos de uso.
|
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
CN109734813B
(zh)
|
2019-01-28 |
2022-06-17 |
广东昭泰体内生物医药科技有限公司 |
一种嵌合抗原受体及其应用
|
|
CN118546959A
(zh)
|
2019-03-05 |
2024-08-27 |
恩卡尔塔公司 |
Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
|
|
WO2020186101A1
(en)
|
2019-03-12 |
2020-09-17 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
RU2742000C2
(ru)
*
|
2019-03-13 |
2021-02-01 |
Общество С Ограниченной Ответственностью "Анабион" |
Выделенный альтернативный внутриклеточный сигнальный домен химерного антигенного рецептора и включающий его химерный антигенный рецептор
|
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
|
MX2021013359A
(es)
*
|
2019-04-30 |
2022-01-31 |
Crispr Therapeutics Ag |
Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19.
|
|
JP7741732B2
(ja)
|
2019-05-07 |
2025-09-18 |
グレイセル・バイオテクノロジーズ（シャンハイ）カンパニー・リミテッド |
Ｂｃｍａを標的とする操作された免疫細胞及びその使用
|
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
US20220249565A1
(en)
*
|
2019-06-27 |
2022-08-11 |
Eutilex Co., Ltd. |
Chimeric antigen receptor with 4-ibb costimulatory domain
|
|
EP3990009A1
(en)
*
|
2019-06-27 |
2022-05-04 |
CRISPR Therapeutics AG |
Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
|
|
CN119955732A
(zh)
*
|
2019-06-27 |
2025-05-09 |
优特力克斯有限公司 |
具有4-1bb共刺激结构域的嵌合抗原受体
|
|
CN110305849B
(zh)
*
|
2019-08-01 |
2021-03-30 |
广东万海细胞生物科技有限公司 |
稳定表达car的t细胞及其制备方法与应用
|
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
|
US20210139850A1
(en)
*
|
2019-11-13 |
2021-05-13 |
Crispr Therapeutics Ag |
Manufacturing process for making t cells expressing chimeric antigen receptors
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
CN115484978A
(zh)
|
2020-03-05 |
2022-12-16 |
尼奥克斯医疗有限公司 |
使用免疫细胞治疗癌症的方法和组合物
|
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技（香港）有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
|
JP2023540361A
(ja)
|
2020-09-08 |
2023-09-22 |
アメリカ合衆国 |
養子細胞療法に対する応答に関連するｔ細胞表現型
|
|
EP4243937A2
(en)
|
2020-11-13 |
2023-09-20 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
|
|
AU2021401052A1
(en)
|
2020-12-18 |
2023-06-22 |
Century Therapeutics, Inc. |
Chimeric antigen receptor systems with adaptable receptor specificity
|
|
US20240316199A1
(en)
|
2020-12-30 |
2024-09-26 |
Alaunos Therapeutics, Inc. |
Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof
|
|
WO2022165419A1
(en)
|
2021-02-01 |
2022-08-04 |
Kyverna Therapeutics, Inc. |
Methods for increasing t-cell function
|
|
WO2022180586A1
(en)
*
|
2021-02-25 |
2022-09-01 |
Senthil Natesan |
Car t-cell product and method of preparation thereof
|
|
EP4298250A1
(en)
|
2021-02-26 |
2024-01-03 |
Fundació Institut de Recerca Contra la Leucèmia Josep Carreras |
Markers of prediction of response to car t cell therapy
|
|
EP4376873A1
(en)
*
|
2021-07-26 |
2024-06-05 |
CRISPR Therapeutics AG |
Methods for manufacturing genetically engineered car-t cells
|
|
CA3228773A1
(en)
*
|
2021-08-12 |
2023-02-16 |
Gaurav KHARYA |
Chimeric antigen receptors (car) for b cell malignancies
|
|
EP4384211A1
(en)
|
2021-08-13 |
2024-06-19 |
Ludwig-Maximilians-Universität München |
Anti-csf1r car expressing lymphocytes for targeted tumor therapy
|
|
KR20240099280A
(ko)
*
|
2021-10-18 |
2024-06-28 |
카이트 파마 인코포레이티드 |
키메라 항원 수용체에 대한 신호전달 도메인
|
|
JP2025501259A
(ja)
|
2021-12-31 |
2025-01-17 |
アメリカ合衆国 |
がんに対する組合せ免疫療法としてのワクチン接種を伴うｔ細胞療法
|
|
US20230210900A1
(en)
|
2022-01-04 |
2023-07-06 |
Kyverna Therapeutics, Inc. |
Methods for treating autoimmune diseases
|
|
EP4572772A1
(en)
|
2022-08-17 |
2025-06-25 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
|
AU2024213852A1
(en)
|
2023-01-30 |
2025-07-03 |
Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) |
Anti-cd86 car expressing lymphocytes for targeted tumor therapy
|
|
US20240285762A1
(en)
|
2023-02-28 |
2024-08-29 |
Juno Therapeutics, Inc. |
Cell therapy for treating systemic autoimmune diseases
|
|
WO2024249954A1
(en)
|
2023-05-31 |
2024-12-05 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2025006799A1
(en)
|
2023-06-27 |
2025-01-02 |
Capstan Therapeutics, Inc. |
Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
|
|
WO2025049631A1
(en)
*
|
2023-08-28 |
2025-03-06 |
Kyverna Therapeutics, Inc. |
Allogeneic car-t cell therapies and manufacture thereof
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
WO2025076127A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
US20250144234A1
(en)
|
2023-11-02 |
2025-05-08 |
Capstan Therapeutics Inc. |
RNA for In vivo Transfection with Increased Expression
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
WO2025129201A1
(en)
|
2023-12-15 |
2025-06-19 |
Capstan Therapeutics, Inc. |
Humanized anti-cd8 antibodies and uses thereof
|
|
WO2025147545A1
(en)
|
2024-01-03 |
2025-07-10 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids and related methods and uses
|
|
WO2025160480A1
(en)
|
2024-01-26 |
2025-07-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1
|
|
WO2025179294A2
(en)
|
2024-02-22 |
2025-08-28 |
Capstan Therapeutics, Inc. |
Immune engineering amplification
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025250587A1
(en)
|
2024-05-29 |
2025-12-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Drug-regulatable, inducible cytokine expression
|